Asset profile
Matsupexole (KDT-3594)
Small molecule
Evidence outlook · lead readout
NCT03845387 · Parkinson Disease
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT03845387: The study randomly assigned 74 participants to KDT-3594 or active treatment with pramipexole, but neither participants nor investigators were blinded. Its primary endpoint was the clinical MDS-UPDRS score at 12 weeks; because no results or statistical comparison are posted, whether this endpoint was met is unknown.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.